See our GUINNESS WORLD RECORDS™ title!

Learn More

Science Starts Here: Wendy Brodeur

At Broad Clinical Labs (BCL), the expertise behind our operations is powered by dedicated professionals who ensure that our science is accurate, reliable, and ready to make a real impact. In this Q&A, we’re spotlighting Wendy Brodeur, our Director of Regulatory, Quality, and Compliance, who shares how she found her way into this specialty, what motivates her work, and why she believes science starts at BCL.

 

What do you do at Broad Clinical Labs?

My title is Director of Regulatory, Quality, and Compliance. I manage BCL’s Quality, Compliance, and Regulatory programs, oversee policies, customer and regulatory audits, and quality systems and applications to ensure full regulatory alignment and quality results. Our work helps maintain a culture of quality, accountability, and continuous improvement for important scientific research, as well as the understanding, diagnosis, and treatment of disease.

 

What drew you to this field of work?

I honestly never expected to end up in quality and regulatory work. I started out in biology, chemistry, and biotech applications, mostly in the R&D world. But over time, I realized how much stronger and more scalable good science becomes when it’s backed by a solid quality system. Clear procedures and structured practices don’t just keep things organized—they turn interesting research into something that can actually make a real impact.

 

As I got more exposure to how research translates into identifying and treating clinical diseases, I found myself getting pulled in. It blended everything I enjoy: science, clinical applications, operations, and the challenge of building scalable systems that protect data integrity and patients. That combination is what ultimately drew me into this side of science.

 

What is something that you’ve worked on while at GP/BCL that you’re especially proud of?

Honestly, the COVID testing launch was an unforgettable milestone—one of those career moments I’ll always be proud of and grew a ton from. But what really makes me proud is the bigger picture: how far we’ve come overall. Our quality systems, our clinical offerings, the maturity of our processes…it’s been incredible to watch it all level up. And now, being able to walk into clinical and customer audits feeling confident and excited to show off what we’ve built—that’s a totally different kind of adrenaline that I’m always happy to be a part of.

 

What keeps you motivated and/or inspired in your role?

What keeps me motivated is knowing that the work we do in the quality and compliance realm actually pushes science forward in a meaningful way. When our systems are solid, the data is stronger, the discoveries are more real, and the diagnostics we support actually help patients get the answers they need. It’s pretty inspiring to feel like the work behind the scenes can make a real difference in someone’s life. One thing I find satisfying is taking a regulation and thinking creatively about how it works in our specific situation while keeping us compliant.

 

In your own words, how or why does #ScienceStartHere – at BCL?

Science starts here because having solid quality and compliance systems is what turns ideas into real, trustworthy results.

 

When not in the office/lab, what are some things you enjoy doing?

I enjoy watching and playing soccer with my kids (we eat, breathe and sleep soccer right now), snowboarding, exploring and wandering (and getting lost) with my pup, art, anything involving the ocean, and traveling.

Return to the Blog

Sean Hofherr

Chief of Clinical Strategy and Product Development, Broad Clinical Labs

Sean Hofherr is dual board certified by ABMGG in Clinical Biochemical Genetics and Clinical Molecular Genetics. Sean serves as the Chief of Clinical Strategy and Product Development at Broad Clinical Labs. In this role at BCL, Sean is able to leverage his extensive experience to guide the clinical vision and delivery across the organization. Sean most recently served as the Chief Operating Office at Fabric Genomics, which focuses on the use of AI and Bioinformatics for Clinical Interpretation of whole genome sequencing. Prior to Fabric, Sean was the Chief Scientific Officer and CLIA Director at the commercial reference laboratory, GeneDx.

Sean received his B.S. degree in Microbiology and Cell Sciences from the University of Florida before earning his Ph.D. in Molecular and Human Genetics from Baylor College of Medicine. Sean completed clinical fellowships in Clinical Biochemical Genetics and Clinical Molecular Genetics at the Mayo Clinic.

Danielle Perrin

Chief of Staff, Broad Clinical Labs

As Broad Clinical Labs’ Chief of Staff, Danielle Perrin advises and supports colleagues on the executive leadership team in BCL’s strategic planning and execution. She builds and leads new organizational functions and processes and leads critical projects, as well as driving effective information flow, decision making, and execution throughout the organization. An operations leader with a business, engineering, and biology background and 20+ years of experience in the genomics field, Perrin has a track record of driving operational excellence and building and scaling both physical and business processes. During her career at Broad, which started in 2003 at the tail end of the Human Genome Project, Perrin has led laboratory operations and R&D teams in Broad’s Genomics Platform, as well as fulfilling senior advisory and leadership roles in the Broad Institute’s COO and CFO offices.

Perrin received her B.S. in Biology and M.E. in Biotechnology Engineering from Tufts University and her M.B.A. from the MIT Sloan School of Management.

Tim De Smet

Chief Commercial Officer, Broad Clinical Labs

As Chief Commercial Officer of Broad Clinical Labs, Tim De Smet leads BCL’s business development, alliance management, external project management, and customer support teams. A Broad Institute employee since 2008, De Smet has held leadership roles and managed teams of various sizes in Broad’s Genomics Platform and clinical lab, spanning laboratory operations, finance, and informatics, and has expertise in work design, financial modeling, and high scale laboratory and business operations.

De Smet received his B.S. in Biochemistry and M.B.A. from Northeastern University.

Jim Meldrim

Chief Technology Officer, Broad Clinical Labs

As Chief Technology Officer, Jim Meldrim sets the vision for Broad Clinical Labs’ informatics systems, including the hardware and software used for sample intake and tracking, data production, analysis, and delivery. Having held a variety of laboratory and informatics-focused leadership roles at Broad, spanning R&D and production operations, Meldrim has been a leader and innovator in the generation, management, and analysis of genomic data since 1999, beginning with sequencing data generation for the Human Genome Project.

Meldrim received his B.S. in Biology from Cornell University.

Sheila Dodge

Chief Operating Officer, Broad Clinical Labs

As Chief Operating Officer, Sheila Dodge leads Broad Clinical Labs’ process development and implementation activities, as well as lab operations, financial planning and operations, quality & compliance, and core business processes. A Six Sigma Black Belt with extensive experience in process development and high throughput genomics operations, Dodge is an expert in work design and in collaborating with a range of collaborators, scientists, engineers, and technology partners to rapidly integrate new technologies and operationalize innovations. A member of the Broad Institute since 2001, Dodge is an Institute Scientist and lectures at the MIT Sloan School of Management on operations, dynamic work design, and visual management techniques.

Dodge received her B.A. in biochemistry and molecular biology from Boston University and her master’s degree in biology from Harvard University. She earned her M.B.A. from MIT Sloan School of Management.

Heidi Rehm, Ph.D., FACMG

Chief Medical Officer and Clinical Laboratory Director, Broad Clinical Labs

Heidi Rehm is board-certified by ABMGG in Clinical Molecular Genetics and Genomics and serves as BCL’s Chief Medical Officer and Clinical Laboratory Director. She oversees BCL’s regulatory requirements, leads the clinical team performing genomic interpretation and variant analysis, and guides BCL’s efforts in genomic testing for clinical and research use. She is also an Institute Member of the Broad and co-director of the Medical and Population Genetics Program. Rehm is also the Chief Genomics Officer in the Department of Medicine and Genomic Medicine Unit Director at the Center for Genomic Medicine at Massachusetts General Hospital, working to integrate genomics into medical practice. She is a principal investigator of ClinGen, providing free and publicly accessible resources to support the interpretation of genes and variants. She co-leads both the Broad Center for Mendelian Genomics, focused on discovering novel rare disease genes, and the Matchmaker Exchange, which aids in gene discovery. She is Chair of the Global Alliance for Genomics and Health, a principal investigator of the Broad-LMM-Color All of Us Genome Center, co-leader of the Genome Aggregation Database (gnomAD), and a Board Member and Vice President of Laboratory Genetics for the American College of Medical Genetics and Genomics.

Rehm received her B.A. degree in molecular biology and biochemistry from Middlebury College before earning her M.S. in biomedical science from Harvard Medical School and Ph.D. in genetics from Harvard University. She completed her post-doctoral training with David Corey in neurobiology and a fellowship in clinical molecular genetics at Harvard Medical School.

Niall Lennon, Ph.D.

Chair and Chief Scientific Officer, Broad Clinical Labs

As Chair and Chief Scientific Officer of Broad Clinical Labs, Niall Lennon leads the team and sets the scientific and clinical vision for the organization. Dr. Lennon joined the Broad Institute in 2006 and has since contributed to the development of applications for every major massively parallel sequencing platform across a range of fields. In 2013 Dr. Lennon led the effort to establish a CLIA licensed, CAP-accredited clinical laboratory at the Broad Institute to facilitate return of results to patients and to support clinical trials. More recently, he has led efforts to achieve FDA approval for large-scale genomics projects (NIH’s All of Us Research Program) and for Broad’s own clinical diagnostic for COVID-19 testing operation, which returned 37+ million results to patients. Dr. Lennon is a principal investigator of the eMerge and All of Us projects, an Institute Scientist at Broad, Associate Director of Broad’s Gerstner Center for Cancer Diagnostics, and an adjunct professor of biomedical engineering at Tufts University, where he teaches Molecular Biotechnology.

Dr. Lennon received a Ph.D. in pharmacology from University College Dublin and completed his postdoctoral studies at Harvard Medical School and Massachusetts General Hospital. He holds an executive certificate in management from the MIT Sloan School of Management.